EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1 prescription(s) fill for BGF on or following July 24, 2020 (date of BGF approval in the United States)
* Patients must have evidence a qualifying exacerbation events which, per local or global guidelines, would qualify a patient to have treatment escalated or initiated to triple therapy. The qualifying exacerbation event must occur within the 12-month period preceding the initiation of BGF but occurring on or following local BGF commercial availability (July 24, 2020) and includes either of the following
12 months of continuous health plan enrollment preceding the qualifying index exacerbation event date ('baseline' period)
1 day of continuous enrollment following the qualifying index exacerbation date
* Age ≥ 40 years on the qualifying index exacerbation event
You may not be if
Presence of cancer diagnoses other than basal or squamous cell skin cancer during the baseline or follow-up periods
Presence of interstitial fibrosis, sarcoidosis, or pulmonary embolism diagnoses during the baseline or follow-up periods
Presence of triple therapy SITT during the baseline period through BGF initiation
Clareo Health | EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
